Press Releases

Project delivered under a US$41 million transaction as part of the 21 MW DC Honeywell portfolio in upstate New York7.01 MW DC ground-mount solar facility now operational, capable of powering approximately 875 homes with clean energy annuallyProject expected to operate as a community solar site, selling credits to subscribers under the NYSERDA NY-Sun ProgramTORONTO, June 25, 2026 /PRNewswire/ - PowerBank Corporation (NASDAQ:PBK) (Cboe CA: PBK) (FSE: 103) ("PowerBank" or the "Company"), a leader in independent energy development and asset ownership in North America, today announces that the 7.01 MW DC / 5 MW AC ground-mount community solar project known as SB 13-2 (the "Project"), located in u

NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Carolyn Starrett to its Board of Directors. Ms. Starrett brings over 25 years of commercial, product, and operations experience at data and technology companies, and a deep understanding of AI and data insights in cancer care and research. She spent the last ten years, from 2016 to 2026, at Flatiron Health, serving in a variety of executive roles and ultimately leading the company as CEO and Board Director from April 2021 to September 2025. She is currently the President of Starrett Advisory, an independent consulting and strategic advisory

Environmental, health, and safety solution is part of Veeva Quality Cloud and will deliver real-time insights and streamlined workflowsPLEASANTON, Calif., June 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE:VEEV) today announced Veeva EHS, a new application in Veeva Quality Cloud for environmental, health, and safety. With Veeva EHS, manufacturing and testing sites can proactively identify, manage, and mitigate operational and environmental risks and ensure global compliance readiness. "A modern EHS solution that simplifies processes through unified data and a seamless user experi

This news release constitutes a "designated news release" for the purposes of the Company's amended and restated prospectus supplement dated June 16, 2026 to its short form base shelf prospectus dated October 31, 2025.San Antonio, Texas--(Newsfile Corp. - June 25, 2026) - HIVE Digital Technologies Ltd. (TSX:HIVE) (NASDAQ:HIVE) (FSE: YO0) (BVC: HIVECO) (the "Company" or "HIVE"), today announces it has signed a letter of intent ("LOI") with an investment-grade, sovereign Swedish technology company (the "Client") for an up to 10 year lease of the Company's 32 megawatt ("MW") Boden, Sweden facility. The LOI is non-binding and subject to the negotiation and execution of a definitive agreement. As

Live virtual fireside chat - investors, advisors, and life sciences analysts invited to attendKing of Prussia, Pennsylvania--(Newsfile Corp. - June 25, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will participate in a fireside chat with Harvey Briggs, Chief Communications Officer, Force Family Office. Joining them will be James Cardia, Ph.D., who will explore siRNA therapy and skin cancer treatments. "We are excited to take part in this

ORLANDO, Fla., June 25, 2026 /PRNewswire/ -- Darden Restaurants, Inc. (NYSE:DRI) today reported its financial results for the fourth quarter and fiscal year ended May 31, 2026, which included a 53rd week of operations compared to 52 weeks last year. Fourth Quarter 2026 Financial HighlightsTotal sales increased 13.7% to $3.72 billion driven by 7.6% in additional sales from an extra week of operations, a blended same-restaurant sales1 increase of 4.6%, and sales from 43 net new restaurantsSame-restaurant sales:               ‌Consolidated Darden14.6 %Olive Garden2.4 %LongHorn Steakhouse9.5 %Fine Dining1.9 %Other Business14.6 %Reported diluted net earnings per share from continuing operations w

BEIJING, June 25, 2026 /PRNewswire/ -- Yiren Digital Ltd. (NYSE:YRD) ("Yiren Digital" or the "Company"), a leading fintech company specializing in digital consumer lending, insurance and financial technology innovation across China and global markets, today announced its unaudited financial results for the first quarter ended March 31, 2026. First Quarter 2026 Operational ResultsCredit Solution BusinessTotal loans facilitated in the first quarter of 2026 were RMB8.9 billion (US$1.3 billion), representing a decrease of 26% compared to RMB12.0 billion in the fourth quarter of 2025, and a decrease of 42% compared to RMB15.2 billion in the same period of 2025.Number of borrowers served in the fi

NEW YORK, June 25, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced its intent to offer, subject to market conditions and other factors, $200.0 million aggregate principal amount of Convertible Senior Notes due in 2032 (the "Notes") in an underwritten offering (the "Offering"). Nuvation Bio also intends to grant the underwriters of the Notes a right to purchase, exercisable within 30 days of the date of the prospectus supplement relating to the Offering, up to an additional $30.0 million aggregate principal amount of Notes, solely to cover over-allotments, if

TORONTO, June 25, 2026 /PRNewswire/ - IsoEnergy Ltd. ("IsoEnergy") (NYSE:ISOU) (TSX:ISO) is pleased to announce the completion of its previously announced acquisition of Toro Energy Limited ("Toro") (ASX: TOE) by way of a scheme of arrangement under Australia's Corporations Act 2001 (Cth) (the "Transaction" or the "Scheme"). Pursuant to the Scheme, IsoEnergy has acquired all of the issued and outstanding ordinary shares of Toro that it does not already own (the "Toro Shares"). The Scheme was implemented today following approval by Toro shareholders on June 9, 2026, and approval by the Federal Court of Australia on June 15, 2026. The Scheme became effective on June 16, 2026.

BEIJING, June 25, 2026 /PRNewswire/ -- Uxin Limited ("Uxin" or the "Company") (NASDAQ:UXIN), a leading used car retailer in China, today hosted its 2026 Investor Day at its warehouse-style superstore in Xi'an. Representatives from leading domestic and international financial institutions and investment firms attended the event, including China International Capital Corporation, China Merchants Securities, Deutsche Bank, Invesco Great Wall Fund Management, Keensight Fund Management, New Top-Founder Investment Management, Shanghai Qingcong Investment Management, Shenwan Hongyuan Securities, and Tian Feng Securities. During the event, participating institutions toured Uxin's Xi'an Superstore an

KITCHENER, ON, June 25, 2026 /PRNewswire/ -- Canadian Solar Inc. (the "Company" or "Canadian Solar") (NASDAQ:CSIQ) today announced that e-STORAGE, its energy storage solutions business, has entered into a supply agreement with an electric utility in Florida to deliver a 95 MW/426 MWh (DC) battery energy storage system (BESS). The battery installation is planned for the second half of 2027, with commercial operation targeted for early 2028. e-STORAGE will provide its proprietary 'SolBank' battery pack powered by its lithium-Ion phosphate-based battery cells, all produced at Canadian Solar's manufacturing facilities, giving the customer full supply chain visibility and compliance. Under the ag

Dollar Tree, Inc. (NASDAQ:DLTR) (the "Company" or "Dollar Tree") today announced that certain funds affiliated with Mantle Ridge LP ("Mantle Ridge") and a selling stockholder that is counterparty to derivative agreements with affiliates of Mantle Ridge (collectively, the "Selling Stockholders") have launched a secondary block trade (the "block trade") to sell 12,820,400 shares of the Company’s common stock (the "common stock") to J.P. Morgan and Goldman Sachs & Co. LLC (collectively, the "broker-dealers"). Mantle Ridge’s sale was made pursuant to Rule 144 under the Securities Act of 1933, as amended. The Company is not selling any shares in the block trade and will not receive any direct pr

Approval of pediatric strategy validates clinical data package and accelerates the regulatory path for CORDStrom™ in the United Kingdom BOCA RATON, Fla, June 25, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that the UK Medicines & Healthcare products Regulatory Agency (MHRA) has approved the Pediatric Investigation Plan (PIP) for Ebstrocel™ for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB). The approval of the PIP is the first required stage toward a Marketing Authorization Application (MAA) submission in the United Kingdom. This regulatory milestone

Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Jonathan ("Jay") Mazelsky to the Company’s Board of Directors, effective July 1, 2026. Mr. Mazelsky joins the Board as an independent director. "We are pleased to welcome Jay to Insulet’s Board of Directors," said President and CEO Ashley McEvoy. "Jay has a strong track record of translating science into solutions to drive growth and create significant and enduring shareholder value. His background and expertise will be integral as Insulet continues to expand access and further strengthen Omnipod’s leaders

Revenue of $19.6 billion, an increase of 31.0% year over year, 29.1% in constant currency(1), and significantly above the high end of our outlook. Non-GAAP gross billings(1) of $28.9 billion, an increase of 33.4% year over year, 31.7% in constant currency(1), and significantly above the high end of our outlook. Diluted earnings per share ("EPS") of $4.15, and non-GAAP diluted EPS(1) of $4.85, an increase of 62.2% year over year and significantly above the high end of our outlook. Returned $151 million to stockholders in the form of $112 million of share repurchases and $39 million in dividends. Announced a quarterly cash dividend of $0.48 per common share, up 9% year over year.

First Zeta-navigated TMS treatments have begun at HOPE Therapeutics clinics in West Palm Beach and Sarasota, Florida, marking the transition from research deployment to active patient careAI-powered, sub-millimetric image guidance is now being applied in HOPE's outpatient TMS workflows for patients with Major Depressive Disorder and other CNS conditionsMilestone advances HOPE's interventional psychiatry platform and aligns with NRx's planned trial of NRX-101 in combination with robotic-enabled TMS in civilian and military treatment facilities (the SPARC-TMS trial). WILMINGTON, Del., June 25, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", "NRx" or

Constellation Energy Generation, LLC ("Constellation"), a Pennsylvania limited liability company, announced today that it has extended the expiration date for each of its offers to exchange any and all of its outstanding unregistered notes listed below that were originally issued in private offerings for equal principal amounts of new issues of notes registered under the Securities Act of 1933, as amended. The exchange offers, which were originally scheduled to expire at 5:00 p.m., New York City time, on Wednesday, June 24, 2026, have been extended until 5:00 p.m., New York City time, on Friday, July 10, 2026, unless further extended. All other terms, provisions and conditions of the exch

Prospera selected as exclusive donor-derived cell-free DNA (dd-cfDNA) monitoring assay for use in Eledon’s planned Phase 3 trial of tegoprubart in kidney transplantation, expected to initiate in late 2026Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, and Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN), a clinical stage biotechnology company developing immune-modulating therapies for the management and treatment of life-threatening conditions, today announced a strategic partnership to incorporate Natera’s Prospera kidney transplant assessment test into Eledon’s planned Phase 3 clinical trial of tegoprubart, an investigational therapy designed to prevent organ

Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced completion of patient enrollment in its Phase 2 clinical study evaluating GLK-321 for the treatment of Demodex blepharitis. GLK-321 is an investigational drug candidate using Glaukos’ proprietary iLution platform, a novel ophthalmic drug-delivery system utilizing patented, cream-based drug formulations applied to the outer surface of the eyelids to enable dropless transdermal delivery of pharmaceutically active compounds for the treatment of eye disorders. The platform is designed to

LONDON and GAITHERSBURG, Md., June 25, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announced that the Company will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. Autolus Chief Executive Officer Dr. Christian Itin will present in a Fireside Chat on Tuesday, June 30, 2026 at 9:00am EDT / 14:00pm BST. A webcast of the fireside chat will be available on the "Events" page in the "Investor Relations & Media" section of the Company’s website at https://www.autolus.com/investor-relations-media/events/. A replay of